Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.

Lung cancer (Amsterdam, Netherlands) - 1 May 2023

Shirasawa Masayuki, Yoshida Tatsuya, Shiraishi Kouya, Takigami Ayako, Takayanagi Daisuke, Imabayashi Tatsuya, Matsumoto Yuji, Masuda Ken, Shinno Yuki, Okuma Yusuke, Goto Yasushi, Horinouchi Hidehito, Yotsukura Masaya, Yoshida Yukihiro, Nakagawa Kazuo, Tsuchida Takaaki, Hamamoto Ryuji, Yamamoto Noboru, Motoi Noriko, Kohno Takashi, Watanabe Shun-Ichi, Ohe Yuichiro

Abstract excerpt

BACKGROUND: Platinum etoposide plus anti-programmed cell death ligand-1 (PD-L1) antibody therapy is the standard of care for extensive-stage small cell lung cancer (ES-SCLC). However, patient characteristics associated with the efficacy of the combination therapy in SCLC are unclear. METHODS: We retrospectively reviewed post-surgical limited-stage (LS)-SCLC and ES-SCLC patients treated with atezolizumab plus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Etoposide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Phenotype

Share to Small Cell Lung Carcinoma

Source

Identifiers

PMID: 37037178
DOI: 10.1016/j.lungcan.2023.107183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.PMID 37037178Read ↗

Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-ResistanceSemantic proximity Read ↗

Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future PerspectivesSemantic proximity Read ↗

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studySemantic proximity Read ↗

Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity Read ↗

Who Will Benefit Most From PD-L1 Detection and Immunotherapy in Non-small Cell Lung Cancer?Semantic proximity Read ↗

Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung CancerSemantic proximity Read ↗

An Immune-related Lncrna Signature Predicts Prognosis and Adjuvant Chemotherapeutic Response in Patients With Small-cell Lung CancerSemantic proximity Read ↗

Molecular phenotypes stratify small cell lung cancer for targeted therapy and immunotherapy.Semantic proximity Read ↗

Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort studySemantic proximity Read ↗

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read ↗

Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer.Semantic proximity Read ↗

PD ‐ L1 and PD ‐ L2 expression correlated genes in non‐small‐cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.